RecruitingNot Applicable

DESTINY-PANTUMOUR04

United States100 participantsStarted 2025-09-18

Plain-language summary

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Who can participate

Age range18 Years – 130 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged ≥18 years

Exclusion criteria

✕. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;
✕. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;
✕. Patients who are willing and able to provide a signed and dated informed consent.
✕. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;
✕. Prior T-DXd therapy;
✕. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.
✕. Patient is participating in a clinical trial at time of enrolment

What they're measuring

Real world response rate (rwRR)

Timeframe: Through study completion, up to 2.5 years after enrolment

Real world duration of response (rwDoR)

Timeframe: Through study completion, up to 2.5 years after enrolment

Trial details

NCT IDNCT07124000

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-03-30

Contact for this trial

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

View on ClinicalTrials.gov More Adenocarcinoma (NOS) trials